Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Trillium nets $51.8mm through public sale of common and preferred shares

Executive Summary

Trillium Therapeutics Inc. (immuno-oncology) netted $51.8mm through the public sale of common and preferred shares. The company issued 1.75mm common shares (including the overallotment) at $19.50, and to existing shareholders whose purchase of common shares would result in beneficial ownership exceeding 4.99%, issued 1.1mm Series II non-voting preferred shares (convertible into common). Proceeds will fund development of SIRPaFc, a fusion protein in IND-enabling studies for acute myeloid leukemia and other blood cancers.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO
    • Other

Related Companies